Physician profile

John R Holt

Cardiovascular Disease · Elizabethtown, KY

NPI 1720283187

$7,109.21

in general payments reported to CMS, 2019-2025

39 companies · $765 in 2025

The $765 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,593.40
Education$64.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $999.08 2019-2022
Amgen INC. $834.34 2019-2025 Repatha, Repatha
Novartis Pharmaceuticals Corporation $833.67 2019-2025
Astrazeneca Pharmaceuticals LP $583.13 2019-2025 Farxiga, Andexxa, Brilinta
Janssen Pharmaceuticals, INC $479.12 2019-2022
Merck Sharp & Dohme LLC $390.64 2021-2025 Verquvo
Pfizer INC. $380.44 2019-2025
Sanofi-Aventis U.S. LLC $272.77 2019-2024
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $217.83 2019-2023 Lifevest
E.R. Squibb & Sons, L.L.C. $199.27 2019-2025 Eliquis, Camzyos
Irhythm Technologies, INC. $195.52 2023-2024 Zio Xt Patch, Zio Monitor
Amarin Pharma, INC. $179.96 2021-2022
Esperion Therapeutics, INC. $163.60 2020-2022
Abbott Laboratories $122.53 2022-2023 Pressurewire, Nc Trek Neo
Boston Scientific Corporation $109.87 2020-2025 Bodyguardian, Lux-Dx Insertable Cardiac Monitor
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $105.92 2019-2025 Rybelsus, Ozempic
Bayer Healthcare Pharmaceuticals INC. $103.79 2022-2025
Chiesi USA, INC. $97.61 2019-2025 Kengreal, Cleviprex
Alnylam Pharmaceuticals INC. $95.56 2021-2025 Onpattro
Inari Medical, INC. $77.04 2022
Actelion Pharmaceuticals US, INC. $76.73 2019-2024 Opsumit, Uptravi
Teleflex LLC $66.98 2024 Turnpike
Baxter Healthcare $58.89 2023 Hillrom - Carnation Ambulatory Monitor
Lundbeck LLC $45.20 2019-2020
Lexicon Pharmaceuticals, INC. $45.19 2023-2024 Inpefa
Elutia, INC. $43.40 2020-2023
Vifor Pharma, INC. $42.49 2021
Edwards Lifesciences Corporation $42.34 2024 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Philips North America LLC $32.54 2023
Regeneron Healthcare Solutions, INC. $28.92 2019
Genzyme Corporation $26.84 2019
Medtronic, INC. $25.71 2022
Astellas Pharma US INC $25.45 2019-2020
Kowa Pharmaceuticals America, INC. $25.09 2019
Medtronic Vascular, INC. $18.58 2020
Heartflow, INC. $17.92 2025
Acist Medical Systems, INC. $16.28 2019
Impulse Dynamics (USA) INC. $15.38 2023 Optimizer
Inspire Medical Systems, INC. $13.59 2024 Inspire

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John R Holt

$7,109.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $765 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/123261/john-r-holt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.